期刊文献+

两种卒中风险评估系统对非瓣膜性房颤人群评估结果的比较 被引量:8

Compare of two stroke risk assessment system in patients with non-valvular atrial fibrillation
下载PDF
导出
摘要 目的两种卒中风险评估系统CHADS2和CHA2DS2-VASc对非瓣膜性房颤人群的卒中风险评估。方法对420例非瓣膜性房颤人群,用CHADS2和CHA2DS2-VASc评估系统进行卒中风险评估,比较两种评估系统平均得分以及卒中危险分层的差异。结果 CHADS2平均得分为(1.39±1.39)分,CHA2DS2-VASc平均得分为(2.41±1.93)分,后者明显高于前者(P<0.05)。CHADS2卒中危险分层低危组为34.5%(145/420),中危组为28.8%(121/420),高危组为36.7%(154/420);CHA2DS2-VASc卒中危险分层低危组为16.2%(68/420),中危组为23.3%(98/420),高危组为60.5%(254/420),CHA2DS2-VASc评分低危组明显低于CHADS2,高危组比例要明显高于CHADS2(P<0.05)。结论CHA2DS2-VASc评估得分高于CHADS2,CHA2DS2-VASc评估的抗凝适应人群也更为广泛。 Objective To compare the results of stroke risk assessment system in patients with non-valvular atrial fibrillation u sing CHADS2 and CHA2DS2-VASc. Methods A total of 420 patients with non-valvular atrial fibrillation were evaluated using CHADS2 and CHA2 DS2-VASc, they were divided into three groups according scores: low risk group(scores 0), intermediate risk group(scores 1), high risk group(scores≥2). Compare the average scores and the proportions of three groups of two stroke risk assessment system. Results The average score of CHA2DS2-VASc was significantly higher than that's of CHADS2 (2.41±1.93 vs. 1.39±1. 39,P〈0.05). According to scores of CHADS2,the proportions of low risk groups were 34.5% (145/420),intermediate risk group were 28.8% (121/420), high risk group were 36. 7% (154/420). According to scores of CHA2 DS2 VASc, the proportions of low risk group were 16.2%(68/420),intermediate risk group were 23.3% (98/420),high risk group were 60.5% (254/ 420). CHA2 DS2-VASc compared with CHADS2, the proportion of low-risk group significantly lower than the latter, the proportion of high-risk groups significantly higher than the latter(P〈0.05). Conclusion The scores of CHA2 DS2-VASc is significantly high- er than that's of CHADS2 in patients with non valvular atrial fibrillation,there are more patients needs anticoagulation using stroke risk assessment system CHA2 DS2-VASc.
出处 《重庆医学》 CAS CSCD 北大核心 2013年第32期3894-3895,共2页 Chongqing medicine
关键词 心房颤动 卒中 风险评估 atrial fibrillation stroke risk stratification
  • 相关文献

参考文献15

  • 1Krahn AD,Manfreda J,Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study[J]. Am J Med, 1995,98(5): 476-484. 被引量:1
  • 2Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation[J]. JAMA,2001,285(22) :2864-2870. 被引量:1
  • 3周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1399
  • 4Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study [J]. Stroke, 1991,13(8): 983-988. 被引量:1
  • 5Flaherty MLKB, Woo D, Kleindorfer D, et al. The increas ing incidence of anticoagulant-associated intracerebral hemorrhage[J]. Neurology, 2007,68 ( 2 ): 116-121. 被引量:1
  • 6Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with at- rial fibrillation-executive summary[J]. Circulation, 2006, 114(7): 257-354. 被引量:1
  • 7Solomon MD, Ullal AJ, Hoang DD, et al. Cost effective- ness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation[J]. J Cardiovasc Med, 2012,13(2) : 86-96. 被引量:1
  • 8Van Staa TP, Setakis E, Di Tanna GL, et al. Comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice[J]. J Thromb Haemost,2011,9(1) :39-48. 被引量:1
  • 9黄从新,张澍,马长生,杨延宗,黄德嘉,曹克将,江洪,杨新春,吴书林,商丽华,张奎俊,李莉,丁燕生,马坚,王祖禄,刘少稳,刘旭,董建增,姚焰,陈柯萍,陈明龙,王方正,陈新.心房颤动:目前的认识和治疗建议-2010[J].中华心律失常学杂志,2010,14(5):328-369. 被引量:93
  • 10Camm AJ,Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the taskforce for the management of atrial fibrillation of the European society of cardiology(ESC) [J]. Eur Heart J,2010,31(19) :2369- 2429. 被引量:1

二级参考文献33

共引文献1477

同被引文献57

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1399
  • 2孙艺红.心房颤动与脑卒中[J].中华全科医师杂志,2006,5(1):10-11. 被引量:14
  • 3张大喜,李红祥,刘献华,等.房颤119例抗凝治疗现状分析[J].医学信息,2013(29):490-490. 被引量:1
  • 4王方芳,韩江莉.非瓣膜病性心房颤动预防脑卒中的药物治疗新进展[J].中华临床医师杂志2013,7(2):769-772. 被引量:1
  • 5易丹,裴奇,周于禄,黄琪,刘世坤.大豆异黄酮对华法林在人体内药动学和药效学的影响[J].中国新药与临床杂志,2007,26(11):821-824. 被引量:3
  • 6Fuster V, Ryd n LE, Cannom DS, et al. ACC, AHA/ESC 2006 Guide- lines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Car- diology Committee for Practice Guidelines (Writing Committee to Re- vise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in eollaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Circulation, 2006,114 (7) : e257 - e354. 被引量:1
  • 7Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip re- placement : a randomised, double - blind, non - inferiority triai [ J]. Lancet, 2007,370 (9 591 ) : 949 - 956. 被引量:1
  • 8Hanon O, Assayag P, Belmin J, et al. Expert consensus of theFrench Society of Geriatrics and Gerontology and the Frech Society of Cardiology on the management of atrial fibrillation in elderly people[J].Arch Cardiovasc Dis, 2013, 10(6):303-323. 被引量:1
  • 9Wolf PA, Abbott RD, Kannel WB. Atrial fibrilla tionasan in depen dentrisk factorforstroke:the Framingham Study[J]. Stroke, 1991 (22):9832988. 被引量:1
  • 10Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals[J]. Circ Cardiovasc Qual Outcomes, 2013(6):543-549. 被引量:1

引证文献8

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部